Tecentriq 840 mg concentrate for solution for infusion clinical trials
8 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN (TMB-H) OR MICROSATELLITE INSTABILITY (MSI-H) (IMperator)
This study looks at new treatments (atezolizumab and tiragolumab) for people with certain solid cancers that have been removed by surgery. It aims to see if these treatments can help stop the cancer from coming back.
For: Solid tumorsSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)
This study looks at new treatments for a type of lung cancer that has not spread widely. It compares two drug combinations to see which is better at stopping the cancer from growing after initial treatment.
For: Non−small cell lung cancer (NSCLC)Poland · Spain · Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer
This study looks at a new way to scan for breast cancer using a special dye and a PET/CT scan. It compares this new scan with a standard test to see how well they match. The goal is to better understand and treat advanced triple-negative breast cancer.
For: Metastatic triple negative breast cancerSweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
"neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)
This study is testing new ways to treat a type of breast cancer called Triple Negative Breast Cancer (TNBC) before surgery. It combines two medicines, Tecentriq and Vusolimogene oderparepvec, to see if they are safe and help reduce the amount of cancer. It's an early-stage study.
For: Patients with early-stage Triple Negative Breast CancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Single-Arm Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Platinum-Based Concurrent Chemoradiation
This study is testing a new treatment called Tecentriq for a type of lung cancer that has started to grow but hasn't spread widely. It aims to see if Tecentriq can help keep the cancer from growing for a longer time after standard treatments.
For: Non-Small Cell Lung Cancer (NSCLC)Slovenia · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)
This study is looking at new ways to treat early-stage breast cancer before standard surgery. It's for people with specific types of breast cancer (triple-negative or HER2+). Researchers are testing if certain immune-boosting medicines can help the body fight the cancer better, hoping to improve treatment outcomes.
For: Newly diagnosed · non-metastatic early-stage triple-negative or HER2+ breast cancerFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
This study, called PANOVA-4, is looking at a new treatment combination for a type of advanced pancreatic cancer. It combines gentle electrical fields called TTFields with existing medications (Atezolizumab, Gemcitabine, and Nab-Paclitaxel) to see how well it controls the disease and helps people live longer.
For: Metastatic pancreatic ductal adenocarcinoma (mPDAC)Spain · Germany · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II Combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors
This study is testing a new combination of medicines for adults with liver cancer that has spread too widely to be removed by surgery. It's for people whose cancer has already been treated with a type of immunotherapy. Researchers want to see how well these new combinations work.
For: Unresectable Hepatocellular Carcinoma (HCC)Spain · Italy